Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
26 oct. 2023 16h00 HE
|
Molecular Partners
MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting...
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
13 sept. 2023 01h00 HE
|
Molecular Partners
New preclinical RDT data show that DARPins can be engineered to increase tumor uptake as well as reducing accumulation in kidneys Engineering solutions transferrable across the platform and to a broad...
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
24 août 2023 16h00 HE
|
Molecular Partners
Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected...
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
27 juin 2023 01h00 HE
|
Molecular Partners
RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targeting efficiency and safety over historic...
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
19 juin 2023 12h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
25 mai 2023 17h01 HE
|
Molecular Partners
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens,...
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
16 mai 2023 16h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
11 mai 2023 16h00 HE
|
Molecular Partners
MP0533: Phase 1 trial of MP0533 for AML ongoing; initial recruitment is progressing well, and site expansion is ongoing; initial clinical results on track for Q4 2023 MP0317: Highest dose cohort...
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
14 avr. 2023 01h00 HE
|
Molecular Partners
Targeted radionuclide delivery platform strengthened by new safety and mechanistic dataData includes review of high tumor penetration potential of DARPins and reduced kidney accumulation via DARPin...
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
04 avr. 2023 11h44 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...